Clinical Trials for Lymphoma

201505024

An Open-Label, Multicenter, Phase I/II trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic…

201608007

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Phase III Principal…

201612005

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma Phase I/II Principal Investigator Bartlett, Nancy Disease Site Lymphoid Leukemia; Non-Hodgkin’s Lymphoma Learn more…

201612068

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) Phase III…

201709117

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas Phase I Principal Investigator Ratner, Lee Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201709201

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Phase II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201710050

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Phase III…

201804151

Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients with Follicular Lymphoma Phase I Principal Investigator Bartlett, Nancy Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201807106

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Phase I/II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201811110

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma Phase I/II Principal Investigator Mehta-Shah, Neha Disease Site Hodgkin’s Lymphoma Learn more…

201902041

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Phase III Principal Investigator Bartlett, Nancy…

201904114

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Phase II Principal…

201905026

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Phase N/A Principal Investigator Haroutounian, Simon Disease Site Breast; Hodgkin’s Lymphoma; Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201907002

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age Phase II Principal Investigator Kahl, Brad Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at:…

201908038

A Phase III, Randomized Study of Nivolumab (OPDIVO) Plus AVD or Brentuximab Vedotin (ADCETRIS) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Phase III Principal Investigator Bartlett,…

201908145

Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas Phase II/III Principal Investigator Bartlett, Nancy Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201911028

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients < or...

201912027

Phase I-II Trial of Venetoclax in Combination with R-ICE (V-RICE) Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Phase I/II Principal Investigator Cashen, Amanda Disease Site Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

202001014

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia Phase I Principal Investigator Ghobadi, Armin Disease…

202001157

A MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, EFFICACY,TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF,OBINUTUZUMAB…

202003073

SGN35-31 – A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase III…

202005165

Phase II Trial with Safety Lead-in of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Phase II Principal Investigator Cashen, Amanda Disease Site Non-Hodgkin’s Lymphoma Learn more about this study…

202007154

A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Phase I Principal Investigator Ratner, Lee Disease Site Lymphoid Leukemia; Non-Hodgkin’s Lymphoma Learn more about this study at:…

202008003

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects Phase II Principal Investigator Bartlett, Nancy Disease Site Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

202008005

SRP001: A Phase 1 Study of FSI-189 as Monotherapy and in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Phase I Principal Investigator Bartlett, Nancy Disease Site Non-Hodgkin’s Lymphoma Learn more about this study…

202102066

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects

202102069

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma Phase I Principal Investigator Mehta-Shah, Neha Disease Site Non-Hodgkin’s Lymphoma Learn more about this…

202103199

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) Phase III Principal Investigator Kahl, Brad Disease Site…

202104077

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and…

202105074

A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS) Phase I Principal Investigator Mehta-Shah, Neha Disease Site Mycosis Fungoides Learn more about this study…